PDCD1 and cancer: Due to the important role of the host immune system in cancer, immune checkpoint inhibitors have garnered attention during the last years, especially against cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligands (PDL-1) [40].